Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To compare the efficacy of 5 mg BID of tofacitinib (with and without background MTX) to adalimumab with MTX as measured by American College of Rheumatology 50% improvement (ACR50) response rates at Month 6. To compare the efficacy of 5 mg BID of tofacitinib monotherapy to 5 mg BID tofacitinib with MTX as measured by ACR50 response rates at Month 6.
Critère d'inclusion
- Moderately to severely active rheumatoid arthritis